-+ 0.00%
-+ 0.00%
-+ 0.00%

uniQure seeks FDA priority review for Huntington’s gene therapy AMT-130 BLA

PUBT·09/02/2026 11:06:40
Listen to the news
uniQure seeks FDA priority review for Huntington’s gene therapy AMT-130 BLA
  • uniQure filed a Biologics License Application with the FDA seeking accelerated approval of AMT-130 for Huntington’s disease.
  • The company requested priority review, which could cut the FDA review timeline to six months following the 60-day filing review.
  • A U.K. marketing authorisation application was also submitted to the MHRA for the same gene therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. uniQure NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020705PRIMZONEFULLFEED9819539) on September 02, 2026, and is solely responsible for the information contained therein.